|
1
|
Zijlstra F, Hoorntje JC, de Boer MJ,
Reiffers S, Miedema K, Ottervanger JP, van’t Hof AW and
Suryapranata H: Long-term benefit of primary angioplasty as
compared with thrombolytic therapy for acute myocardial infarction.
N Engl J Med. 341:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Boersma E: Does time matter? A pooled
analysis of randomized clinical trials comparing primary
percutaneous coronary intervention and in-hospital fibrinolysis in
acute myocardial infarction patients. Eur Heart J. 27:779–788.
2006. View Article : Google Scholar
|
|
3
|
Braunwald E and Kloner RA: Myocardial
reperfusion: a double-edged sword? J Clin Invest. 76:1713–1719.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yellon DM and Hausenloy DJ: Myocardial
reperfusion injury. N Engl J Med. 357:1121–1135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peuhkurinen K: Myocardial reperfusion-a
double-edged sword? Duodecim. 105:822–830. 1989.(In Finnish).
|
|
6
|
Burniston JG, Saini A, Tan LB and
Goldspink DF: Angiotensin II induces apoptosis in vivo in skeletal,
as well as cardiac, muscle of the rat. Exp Physiol. 90:755–761.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Re R: Intracellular renin-angiotensin
system: the tip of the intracrine physiology iceberg. Am J Physiol
Heart Circ Physiol. 293:H905–H906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zablocki D and Sadoshima J: Knocking out
angiotensin II in the heart. Curr Hypertens Rep. 13:129–135. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Donoghue M, Hsieh F, Baronas E, Godbout K,
Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan
R, et al: A novel angiotensin-converting enzyme-related
carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9.
Circ Res. 87:E1–E9. 2000.
|
|
10
|
Tipnis SR, Hooper NM, Hyde R, Karran E,
Christie G and Turner AJ: A human homolog of angiotensin-converting
enzyme. Cloning and functional expression as a
captopril-insensitive carboxypeptidase. J Biol Chem.
275:33238–33243. 2000. View Article : Google Scholar
|
|
11
|
Vickers C, Hales P, Kaushik V, Dick L,
Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, et al:
Hydrolysis of biological peptides by human angiotensin-converting
enzyme-related carboxypeptidase. J Biol Chem. 277:14838–14843.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang XP, Liu YH, Shesely EG, Bulagannawar
M, Liu F and Carretero OA: Endothelial nitric oxide gene knockout
mice: cardiac phenotypes and the effect of angiotensin-converting
enzyme inhibitor on myocardial ischemia/reperfusion injury.
Hypertension. 34:24–30. 1999. View Article : Google Scholar
|
|
13
|
Costerousse O, Allegrini J, Clozel JP,
Menard J and Alhenc-Gelas F: Angiotensin I-converting enzyme
inhibition but not angiotensin II suppression alters angiotensin
I-converting enzyme gene expression in vessels and epithelia. J
Pharmacol Exp Ther. 284:1180–1187. 1998.PubMed/NCBI
|
|
14
|
Houston Miller N: Cardiovascular risk
reduction with renin-angiotensin aldosterone system blockade. Nurs
Res Pract. 2010:1017492010.PubMed/NCBI
|
|
15
|
Sim DS, Jeong MH, Kim YH, Choi S, Lim KS,
Kim JH, Cho KH, Kim MC, Kim HK, Kim SS, et al: Effects of
sildenafil in combination with angiotensin-converting enzyme
inhibitor on limiting infarct expansion in a porcine model of acute
myocardial infarction. Int J Cardiol. 146:459–460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Serneri GG, Boddi M, Cecioni I, Vanni S,
Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano
T, et al: Cardiac angiotensin II formation in the clinical course
of heart failure and its relationship with left ventricular
function. Circ Res. 88:961–968. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Both GW: Recent progress in gene-directed
enzyme prodrug therapy: an emerging cancer treatment. Curr Opin Mol
Ther. 11:421–432. 2009.PubMed/NCBI
|
|
18
|
Suckau L, Fechner H, Chemaly E, Krohn S,
Hadri L, Kockskämper J, Westermann D, Bisping E, Ly H, Wang X, et
al: Long-term cardiac-targeted RNA interference for the treatment
of heart failure restores cardiac function and reduces pathological
hypertrophy. Circulation. 119:1241–1252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brosnahan MM, Damiani A, van de Walle G,
Erb H, Perkins GA and Osterrieder N: The effect of siRNA treatment
on experimental equine herpesvirus type 1 (EHV-1) infection in
horses. Virus Res. 147:176–181. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu
M, Abel ED, Xenocostas A and Kvietys PR: Erythropoietin prevents
the acute myocardial inflammatory response induced by
ischemia/reperfusion via induction of AP-1. Cardiovasc Res.
65:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen HP, He M, Huang QR, Liu D and Huang
M: Sasanquasaponin protects rat cardiomyocytes against oxidative
stress induced by anoxia-reoxygenation injury. Eur J Pharmacol.
575:21–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koyama T, Temma K and Akera T:
Reperfusion-induced contracture develops with a decreasing [Ca2+]i
in single heart cells. Am J Physiol. 261:H1115–H1122.
1991.PubMed/NCBI
|
|
23
|
Palojoki E, Saraste A, Eriksson A, Pulkki
K, Kallajoki M, Voipio-Pulkki LM and Tikkanen I: Cardiomyocyte
apoptosis and ventricular remodeling after myocardial infarction in
rats. Am J Physiol Heart Circ Physiol. 280:H2726–H2731.
2001.PubMed/NCBI
|
|
24
|
Fliss H and Gattinger D: Apoptosis in
ischemic and reperfused rat myocardium. Circ Res. 79:949–956. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Danial NN and Korsmeyer SJ: Cell death:
critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arumugam TV, Chan SL, Jo DG, Yilmaz G,
Tang SC, Cheng A, Gleichmann M, Okun E, Dixit VD, Chigurupati S, et
al: Gamma secretase-mediated Notch signaling worsens brain damage
and functional outcome in ischemic stroke. Nat Med. 12:621–623.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martinou JC and Youle RJ: Mitochondria in
apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev
Cell. 21:92–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kharbanda S, Pandey P, Schofield L,
Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S,
Weichselbaum R, et al: Role for Bcl-xL as an inhibitor of cytosolic
cytochrome C accumulation in DNA damage-induced apoptosis. Proc
Natl Acad Sci USA. 94:6939–6942. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kluck RM, Bossy-Wetzel E, Green DR and
Newmeyer DD: The release of cytochrome c from mitochondria: a
primary site for Bcl-2 regulation of apoptosis. Science.
275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Simonis G, Wiedemann S, Schwarz K, Christ
T, Sedding DG, Yu X, Marquetant R, Braun-Dullaeus RC, Ravens U and
Strasser RH: Chelerythrine treatment influences the balance of pro-
and anti-apoptotic signaling pathways in the remote myocardium
after infarction. Mol Cell Biochem. 310:119–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Brocheriou V, Hagège AA, Oubenaïssa A,
Lambert M, Mallet VO, Duriez M, Wassef M, Kahn A, Menasché P and
Gilgenkrantz H: Cardiac functional improvement by a human Bcl-2
transgene in a mouse model of ischemia/reperfusion injury. J Gene
Med. 2:326–333. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hochhauser E, Kivity S, Offen D, Maulik N,
Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub
V, et al: Bax ablation protects against myocardial
ischemia-reperfusion injury in transgenic mice. Am J Physiol Heart
Circ Physiol. 284:H2351–H2359. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ohtsuka T, Ryu H, Minamishima YA, Macip S,
Sagara J, Nakayama KI, Aaronson SA and Lee SW: ASC is a Bax adaptor
and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell
Biol. 6:121–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fridman JS and Lowe SW: Control of
apoptosis by p53. Oncogene. 22:9030–9040. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kumar R, Singh VP and Baker KM: The
intracellular renin-angiotensin system in the heart. Curr Hypertens
Rep. 11:104–110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kumar R and Boim MA: Diversity of pathways
for intracellular angiotensin II synthesis. Curr Opin Nephrol
Hypertens. 18:33–39. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dell’Italia LJ and Husain A: Dissecting
the role of chymase in angiotensin II formation and heart and blood
vessel diseases. Curr Opin Cardiol. 17:374–379. 2002.PubMed/NCBI
|
|
41
|
Singh VP, Le B, Bhat VB, Baker KM and
Kumar R: High-glucose-induced regulation of intracellular ANG II
synthesis and nuclear redistribution in cardiac myocytes. Am J
Physiol Heart Circ Physiol. 293:H939–H948. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ferrario CM, Chappell MC, Tallant EA,
Brosnihan KB and Diz DI: Counterregulatory actions of
angiotensin-(1–7). Hypertension. 30:535–541. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iyer SN, Chappell MC, Averill DB, Diz DI
and Ferrario CM: Vasodepressor actions of angiotensin-(1–7)
unmasked during combined treatment with lisinopril and losartan.
Hypertension. 31:699–705. 1998.PubMed/NCBI
|
|
44
|
Crackower MA, Sarao R, Oudit GY, Yagil C,
Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang
L, Pei Y, et al: Angiotensin-converting enzyme 2 is an essential
regulator of heart function. Nature. 417:822–828. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Thomas MC, Pickering RJ, Tsorotes D,
Koitka A, Sheehy K, Bernardi S, Toffoli B, Nguyen-Huu TP, Head GA,
Fu Y, et al: Genetic Ace2 deficiency accentuates vascular
inflammation and atherosclerosis in the ApoE knockout mouse. Circ
Res. 107:888–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tikellis C, Bialkowski K, Pete J, Sheehy
K, Su Q, Johnston C, Cooper ME and Thomas MC: ACE2 deficiency
modifies renoprotection afforded by ACE inhibition in experimental
diabetes. Diabetes. 57:1018–1025. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Burrell LM, Risvanis J, Kubota E, Dean RG,
MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, et al:
Myocardial infarction increases ACE2 expression in rat and humans.
Eur Heart J. 26:369–375, Discussion 322–364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ferrario CM, Jessup J, Chappell MC,
Averill DB, Brosnihan KB, Tallant EA, Diz DI and Gallagher PE:
Effect of angiotensin-converting enzyme inhibition and angiotensin
II receptor blockers on cardiac angiotensin-converting enzyme 2.
Circulation. 111:2605–2610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Harada E, Yoshimura M, Yasue H, Nakagawa
O, Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T,
et al: Aldosterone induces angiotensin-converting-enzyme gene
expression in cultured neonatal rat cardiocytes. Circulation.
104:137–139. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamamuro M, Yoshimura M, Nakayama M, Abe
K, Sumida H, Sugiyama S, Saito Y, Nakao K, Yasue H and Ogawa H:
Aldosterone, but not angiotensin II, reduces angiotensin converting
enzyme 2 gene expression levels in cultured neonatal rat
cardiomyocytes. Circ J. 72:1346–1350. 2008. View Article : Google Scholar : PubMed/NCBI
|
